Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an
experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in
patients with cancer.